Table 10.
Thrombolytic Agents Approved For The Treatment Of STEMI.
| Agent | Bolus | Dose | Adverse Effects | Fibrin Specificity | Efficacy (TIMI 2 or 3 flow at 90 min) |
|---|---|---|---|---|---|
| Streptokinase (STK) | No | 1.5 million unit given intravenously over 30–60 minutes | Might cause severe hypotension. Allergic reaction. (+nce of anti-Bodies) Avoid re exposure within 6 months. | No | 60 to 68% |
| Tenecteplase (TNK) | Yes | 30 mg for weight 60 kg; 35 mg for 60–69 kg; 40 mg for 70–79 kg; 45 mg for 80–89 kg; and 50 mg for 90 kg | – | +++ | 85% |
| Reteplase (rPA) | Yes (double bolus) | 10U + 10U intravenous boluses given 30 min apart | – | ++ | 84% |
| Alteplase (rt-PA) |
No | Bolus 15 mg, followed by infusion 0.75 mg/kg (maximum 35) over the next 60 min; total dose should not exceed 100 mg | – | ++ | 75–84% |